Markus Loeffler - Concepedia

Author

Markus Loeffler

Also Known As

A. Rosenwald, Balkau, B., Benjamin Lehne, Chris Lawerenz, Christoph B. Ostertag, Dimitri Livitz, F.M. Brunkhorst, Franziska G. Rauscher, Gudbjartsson, Daniel F., Holger Bogatsch

783

Publications

57.7K

Citations

113

H-Index

364

Concepts

All Affiliations

Leipzig University Heidelberg University Heinrich Heine University Düsseldorf Charité - Universitätsmedizin Berlin Saarland University

About

Markus Loeffler is an author at Leipzig University specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	61	138	20.7K
2	Health Sciences	23	36	1.8K
3	Engineering	16	18	991
4	Natural Sciences	5	5	129
5	Language Studies	1	1	19

Markus Loeffler

349

Publications

45.3K

Citations

101

H-Index

Page 1

	Year	Citations
Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis Frank M. Brunkhorst, Christoph Engel, Frank Bloos, New England Journal of Medicine	2008	2.9K
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaMabthera International TrialMedicinePathology	2006	2.1K
Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression Urmo Võsa, Annique Claringbould, Harm-Jan Westra, Nature Genetics Genome-wide Association StudyGenetic AnalysisMedicineGeneticsLarge-scale Cis-	2021	2K
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes Bjoern Chapuy, Chip Stewart, Andrew Dunford, Nature Medicine Hematological MalignancyLymphoid NeoplasiaMolecular SubtypesImmunologyPathology	2018	1.9K
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaElderly PatientsMedicineBi-weekly Chop-14	2008	1.1K
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling Michael Hummel, Stefan Bentink, Hilmar Berger, New England Journal of Medicine	2006	1K
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Christian Hartmann, Bettina Hentschel, Wolfgang Wick, Acta Neuropathologica Unfavorable Prognostic EffectNeuro-oncologyTumor HeterogeneityMedicinePathology	2010	837
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease Volker Diehl, Jeremy Franklin, Michael Pfreundschuh, New England Journal of Medicine	2003	827
A saturated map of common genetic variants associated with human height Loïc Yengo, Sailaja Vedantam, Eirini Marouli, Nature	2022	827
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, The Lancet Oncology Hematological MalignancyLymphoid Neoplasia6-Year ResultsMabthera International TrialMedicine	2011	796

Page 1